Neural Representations of Memory Transformation (MEM_TRANS)

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMedical University of South Carolina

About this trial

Investigators overarching goal is to provide evidence for the link between altered spatiotemporal (where and when) neural mechanisms and the extent of changed memory maintenance in healthy older adults and to identify potential neural markers of compensatory function (cognitive resource). Investigators preliminary studies suggest that healthy older adults, compared to younger adults, benefit behaviorally from increased coupling between frontal and parietal brain waves when retrieving and updating well-consolidated visuomotor sequence memory via stronger top-down cognitive control of memory maintenance. Thus, Investigators central hypothesis is that the dynamics across cortical and subcortical regions (i.e., spatiotemporal representations) during transitions between different levels of memory stability indicate the efficiency of memory maintenance. The rationale is that while temporal and spatial neural signatures carry distinct mechanistic information, the joint definition of spatial and temporal representations will allow the differentiation of compensatory versus neurodegenerative mechanisms.

Eligibility criteria

Qualifiers

Age 18 years or older (80 of the final sample will be ≥60years of age)

Cognitively unimpaired, ambiguous, or mildly impaired cognitive function, defined as a score of ≥18 in the Montreal Cognitive Assessment (MOCA).

No previous stroke, brain tumor, neurodegenerative disease, or trauma to the head

Ability to give consent for study participation

Disqualifiers

Inability to use both index and middle fingers to type on a standard computer keyboard

Dementia defined as a score of <18 in the Montreal Cognitive Assessment (MOCA)

Uncorrected vision, hindering perception of visual cues presented on a standard computer screen

Medication use at the time of study that may interfere with learning, including but not limited to carbamazepine, flunarizine, sulpiride, rivastigmine, and dextromethorphan.

Trial design

Treatments tested in this trial

  • Computer-based visuomotor sequence learning and interference

Treatment groups

40 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Medical University of South Carolina

Lead sponsor

National Institutes of Health (NIH)

Collaborator